Heterologous SH3-p85β inhibits influenza A virus replication
- Dan-gui Zhang†1,
- Wei-zhong Li†1,
- Ge-fei Wang1,
- Yun Su1,
- Jun Zeng1,
- Chi Zhang1,
- Xiang-xing Zeng1,
- Xiao-xuan Chen1,
- Yan-xuan Xu1 and
- Kang-sheng Li1Email author
© Zhang et al; licensee BioMed Central Ltd. 2008
Received: 12 April 2010
Accepted: 23 July 2010
Published: 23 July 2010
Phosphatidylinositol 3-kinase (PI3K)/Akt signalling pathway can support the replication of influenza A virus through binding of viral NS1 protein to the Src homology 3 (SH3) domain of p85β regulatory subunit of PI3K. Here we investigated the effect of heterologously overexpressed SH3 on the replication of different influenza A virus subtypes/strains, and on the phosphorylation of Akt in the virus-infected cells. We found that heterologous SH3 reduced replication of influenza A viruses at varying degrees in a subtype/strain-dependent manner and SH3 overexpression reduced the induction of the phosphorylation of Akt in the cells infected with PR8(H1N1) and ST364(H3N2), but not with ST1233(H1N1), Ph2246(H9N2), and Qa199(H9N2). Our results suggest that interference with the NS1-p85β interaction by heterologous SH3 can be served as a useful antiviral strategy against influenza A virus infection.
Influenza A viruses are globally important human and animal respiratory pathogens, and viral infections cause highly contagious respiratory diseases. Influenza A virus can be divided into numerous subtypes (H1~H16 and N1~N9) according to the antigenicity of hemagglutinin (HA) and neuraminidase (NA). Among them, H1N1 and H3N2 subtypes are the most common subtype in human influenza infections . However, in some situations, several avian influenza virus subtypes (such as H5N1, H7N7, or H9N2) can break through the species barrier and be transmitted to humans . These avian influenza viruses have posed serious threat to public health.
One of the main research emphases in the influenza A virus is its NS1 protein. NS1 can modulate virus infection and host cell signalling pathway [3–6], such as phosphatidylinositol 3-kinase(PI3K)/Akt pathway . The PI3K/Akt pathway plays a central role in modulating diverse downstream signalling pathways associated with cell survival, proliferation, migration, and differentiation [8–10].
PI3K is a dimeric enzyme consisting of a p110 catalytic subunit (α, β, or δ) tethered to a smaller, non-catalytic, regulatory subunit p85 (usually p85α, p85β, p55γ, p55α, or p50α) [11–13]. NS1 can interact with p85β of PI3K via direct binding to SH3 domain of p85β and hence promote the activation of PI3K , whereas mutation within the SH3 binding motif 1 of NS1 is able to deprive NS1-p85β interaction and result in the reduction of virulence of influenza A virus . Apart from SH3, iSH2 domain (inter-SH2) and cSH2 domain (C-terminal SH2) domain of p85β are responsible for NS1-p85β interaction and the subsequent activation of PI3K [14, 16, 17]. NS1-mediated PI3K activation is obviously essential for influenza A virus replication because viral titers are significantly decreased when PI3K is inhibited [18, 19].
We hypothesized that viral replication could be repressed by blocking NS1-p85β interaction (competitively) with heterologously expressed SH3. Since previous studies have shown that NS1-mediated PI3K activation is obviously important for the efficient propagation of influenza A virus [7, 14, 18, 20, 21], in this study, we examined the effect of heterologous SH3 (h-SH3) on (i) the replicability of five strains of influenza A virus from three subtypes (H1N1, H3N2, and H9N2) in infected cells and (ii) the phosphorylation status of Akt after viral infection.
Co-localization of h-SH3 and NS1
Differential suppressive effect of h-SH3 on the replication kinetics of influenza A viruses
Differential suppressive effect of h-SH3 on the phosphorylation status of Akt
Differential roles of PI3K in the replication of ST364 and PR8 viruses
Having demonstrated the suppressive effect of h-SH3 on the phosphorylation status of Akt in the ST364(H3N2)- and PR8(H1N1)-infected cells, we further examined the role of PI3K in the replication of these two viral strains by treating them with the PI3K inhibitor, LY294002 (10 uM or 50 uM), followed by the plaque formation assay. Significant reduction in the number of plaques was observed in the ST364-infected cells, but there was no obvious change with the PR8-infected cells. Treatment with different concentrations (10 uM and 50 uM) of LY294002 showed no obvious difference in replication.
The binding of p85β subunit to the influenza A virus NS1 protein results in the activation of PI3K/Akt pathway, which in turn can promote the viral replication by helping virus entry, viral RNA expression, nuclear export of the RNPs, and preventing premature apoptosis [19, 23]. As NS1 interacts with p85β via direct binding to SH3, iSH2, or cSH2 domain of p85β, it can be speculated that disturb this interaction by heterologously expressed SH3, iSH2, or cSH2 may be a potential anti-influenza strategy. Since iSH2 is also an interactive site of p85β and p110 [16, 17], overexpression of iSH2 may interfere with the formation of PI3K in normal cells. Additionally, given that the relative weak ability of cSH2 in mediating the interaction of p85β and NS1 , only SH3 was thus chosen as a candidate antiviral agent in this study. Our aim was to determine whether the SH3-p85β site in the NS1 could be targeted by heterologously expressed SH3, thereby inhibiting influenza A virus replication.
Subcellular localization in this study showed that in MDCK cells transiently co-expressing NS11, NS32, or NS92, the h-SH3 was colocalized with NS1 in the nucleus (Fig. 1), implying the interaction of NS1 and h-SH3. Combined with the results of Fig. 2, it can be seen that in addition to its recognized interaction with endogenous p85β subunit of PI3K via three binding sites (SH3, iSH2, and cSH2) [14, 16, 17], NS1 can also bind to heterologous SH3 and the interaction is strong enough to result in suppression of viral replication, though the degree of suppression was apparently different among the viral strains.
As Akt-P is the major downstream product of activated PI3K, the Akt-P/Akt-T ratio was used to compare the levels of virus-induced PI3K activation affected by h-SH3 in cells infected with different influenza A viruses. Remarkable elevation of Akt-P could be seen in PR8-, ST364-, Ph2246-, or Qa199-infected cells, but not in ST1233-infected cells. In addition, h-SH3 could reduce the PI3K activation in PR8- or ST364-infected cells, while no alteration was observed in ST1233-, Ph2246-, or Qa199-infected cells (Fig. 3). The reason for this is unclear. As iSH2 domain may be more important than SH3 for NS1-p85β interaction [16, 17], it is reasonable to speculate that for some influenza A virus strains, h-SH3 could not be absolutely essential for the activation of PI3K. Thus, even through h-SH3 can disturb the NS1-p85β interaction, its effect on the activation of PI3K and the ratio of Akt-P/Akt-T may be negligible.
It has been shown that the PI3K/Akt pathway activated by NS1 is beneficial for influenza A virus infection , and influenza A virus titers are significantly decreased when PI3K is inhibited . Interestingly, h-SH3's effect on PI3K/Akt pathway was not well correlated with the replication of some viruses in this study. While h-SH3 could inhibit replication of every strain of influenza A virus to varying degrees, no suppression of PI3K (or PI3K/Akt pathway) was observed in ST1233-, Ph2246-, or Qa199-infected MDCK cells (Fig. 3). The reason may involve the complicated relationship between NS1 and cellular proteins. More than nine cellular proteins were found directly interacted with NS1. Among them, CPSF30 (30 kDa subunit of cleavage and polyadenylation specificity factor) and p85β shared partial overlapped binding sites (SH3 binding motif 1) in NS1 . Moreover, blocking the binding of endogenous CPSF30 to NS1 protein can strikingly inhibit the replication of influenza A virus . Therefore, h-SH3 may also disrupt the interaction of NS1 and CPSF30 and then reduce the replication of some influenza A viruses (such as ST1233, Ph2246, and Qa199) without the reduction of Akt-P/Akt-T ratio.
In conclusion, this study demonstrates that h-SH3 can inhibit the replication of influenza A viruses (H1N1, H3N2, and H9N2) at different degrees, and targeting NS1-p85β interaction (PI3K/Akt pathway) or other virus-host interaction may be an attractive strategy against the infection of various influenza A virus subtypes/strains.
Cell lines, viruses, plasmids, and reagents
Madin-Darby canine kidney (MDCK) cell lines were routinely cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum and antibiotics (100 U penicillin and 100 ug/ml streptomycin) at 37℃ in 5% CO2.
Influenza A virus strains A/PR/8/34(H1N1), A/ST/1233/2006(H1N1), A/ST/364/2005(H3N2), A/Ph/ST/2246/2006(H9N2), and A/Qa/ST/199/2006(H9N2), abbreviated herein to PR8, ST1233, ST364, Ph2246, and Qa199, respectively, were used in this study.
SH3 domain (9-79aa) of p85β subunit was cloned into PNF vector (a modified pcDNA3 plasmid with an N-terminal Flag tag) at the Bam HI and Eco RI sites to generate pSH3. Full-length NS1 sequence of H1N1, H3N2, or H9N2 viruses was cloned into pEGFP-c1 at the Bam HI site to generate pNS11, pNS32, or pNS92 plasmids, respectively. The constructs were verified by DNA sequencing.
Rabbit monoclonal anti-phospho-Akt (Ser473) antibody were purchased from Cell Signaling Technology (Danvers, MA, USA), Rabbit monoclonal anti-Flag antibody from Sigma (St. Louis, MO, USA), Rabbit monoclonal anti-Akt antibody, Cy3-labeled goat anti-rabbit antibody, peroxidase-conjugated goat anti-rabbit antibody, and LY294002 (PI3K inhibitor) from Beyotime Biotechnology (Jiangsu, China), and Lipofectamine 2000 from Invitrogen (Carlsbad, CA, USA).
Co-localization analysis by confocal microscopy
MDCK cell cultures on the glass coverslips were transfected with indicated plasmids. 24 h post-transfection, the cells were washed twice with phosphate-buffered saline (PBS), fixed for 10 min with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100 for 7 min, and incubated for 30 min in PBS containing 3% Bovine Serum Albumin (BSA). Cells were subsequently incubated at room temperature with anti-Flag antibody (1/500) for 2 h and Cy3-labeled secondary antibody (1/300) for 1 h. Images were captured with the Olympus confocal microscopy.
Transient transfection, viral infection, and determination of antiviral activity
MDCK cells were seeded onto six-well plates and transfected with pSH3 or PNF empty vector at 60% confluence as previously described . After 48 h of transfection, MDCK cells were infected with influenza A viruses at a multiplicity of infection (MOI) of 0.001 in serum-free DMEM containing 1 ug/ml TPCK-trypsin (Worthington, Freehold, NJ, USA) and incubated at 37°C. An aliquot of the supernatant was harvested every 12 h and virus yield was titrated by plaque assay in MDCK cells.
Western blot-based phosphorylation assay
MDCK cells transfected with indicated plasmids for 24 h were infected with different influenza A virus strains at an MOI of 2. At 8 h post infection the cells were lysed with Laemmli sample buffer containing 5 mM of NaF for 5 min in boiling water followed by brief sonication. Protein concentration was determined using an RC-DC kit (Bio-Rad, Hercules, CA, USA). Proteins (20 ug/lane) were separated in 10% SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane was blocked with Tris-buffered saline containing 0.1% Tween 20 (TBST) with 10% non-fat milk for 2 h and incubated overnight at 4°C with anti-phospho-Akt (Ser473) (1/500) or anti-Akt (1/700) antibody. The membrane was rinsed extensively in TBST and incubated for 2 h with peroxidase-conjugated secondary antibody (1/1000). Immunoblots were developed using the Enhanced chemiluminescence (ECL) reagents (Pierce, Rockford, IL, USA). Quantity One (Bio-Rad) software was used to analyze images.
Determination of PI3K effect on the replication of ST364 and PR8 viruses
MDCK cells with 100% confluence were pretreated with 10 uM or 50 uM LY294002 (a specific PI3K inhibitor). After 2 h, MDCK cells were infected with ST364 virus or PR8 virus, and plaque assay was performed.
We thank Dr. William Ba-Thein for critical discussion and manuscript editing. This study was supported by National Natural Science Foundation of China (30771988, 30972766), Guangdong Natural Science Foundation(8151503102000022, 9451503102003499), Specialized Research Fund for the Doctoral Program of Higher Education (20094402110004), Outstanding Young Scientists Foundation of Guangdong Province Education Department (LYM08056), State Key Lab of Agriculture Microbiology Open Foundation (AML200910), Shantou University Medical College Research Foundation, and 211 Project of Guangdong Province (Mechanism and Prevention of Emerging Infectious Diseases).
- Nelson MI, Viboud C, Simonsen L, Bennett RT, Griesemer SB, St George K, Taylor J, Spiro DJ, Sengamalay NA, Ghedin E, Taubenberger JK, Holmes EC: Multiple reassortment events in the evolutionary history of H1N1 influenza A virus since 1918. PLoS Pathog 2008, 4: e1000012. 10.1371/journal.ppat.1000012PubMedPubMed CentralView ArticleGoogle Scholar
- Peiris M, Yuen KY, Leung CW, Chan KH, Ip PL, Lai RW, Orr WK, Shortridge KF: Human infection with influenza H9N2. Lancet 1999, 354: 916-917. 10.1016/S0140-6736(99)03311-5PubMedView ArticleGoogle Scholar
- Garcia-Sastre A: Inhibition of interferon-mediated antiviral responses by influenza A viruses and other negative-strand RNA viruses. Virology 2001, 279: 375-384. 10.1006/viro.2000.0756PubMedView ArticleGoogle Scholar
- Garcia-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, Durbin JE, Palese P, Muster T: Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 1998, 252: 324-330. 10.1006/viro.1998.9508PubMedView ArticleGoogle Scholar
- Krug RM, Yuan W, Noah DL, Latham AG: Intracellular warfare between human influenza viruses and human cells: the roles of the viral NS1 protein. Virology 2003, 309: 181-189. 10.1016/S0042-6822(03)00119-3PubMedView ArticleGoogle Scholar
- Hayman A, Comely S, Lackenby A, Murphy S, McCauley J, Goodbourn S, Barclay W: Variation in the ability of human influenza A viruses to induce and inhibit the IFN-beta pathway. Virology 2006, 347: 52-64. 10.1016/j.virol.2005.11.024PubMedView ArticleGoogle Scholar
- Hale BG, Jackson D, Chen YH, Lamb RA, Randall RE: Influenza A virus NS1 protein binds p85beta and activates phosphatidylinositol-3-kinase signaling. Proc Natl Acad Sci USA 2006, 103: 14194-14199. 10.1073/pnas.0606109103PubMedPubMed CentralView ArticleGoogle Scholar
- Brazil DP, Yang ZZ, Hemmings BA: Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004, 29: 233-242. 10.1016/j.tibs.2004.03.006PubMedView ArticleGoogle Scholar
- Cantley LC: The phosphoinositide 3-kinase pathway. Science 2002, 296: 1655-1657. 10.1126/science.296.5573.1655PubMedView ArticleGoogle Scholar
- Cooray S: The pivotal role of phosphatidylinositol 3-kinase-Akt signal transduction in virus survival. J Gen Virol 2004, 85: 1065-1076. 10.1099/vir.0.19771-0PubMedView ArticleGoogle Scholar
- J Yu, Zhang Y, McIlroy J, Rordorf-Nikolic T, Orr GA, Backer JM: Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 1998, 18: 1379-1387.View ArticleGoogle Scholar
- Cantrell DA: Phosphoinositide 3-kinase signalling pathways. J Cell Sci 2001, 114: 1439-1445.PubMedGoogle Scholar
- Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC: Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 2005, 30: 194-204. 10.1016/j.tibs.2005.02.008PubMedView ArticleGoogle Scholar
- Shin YK, Liu Q, Tikoo SK, Babiuk LA, Zhou Y: Influenza A virus NS1 protein activates the phosphatidylinositol 3-kinase (PI3K)/Akt pathway by direct interaction with the p85 subunit of PI3K. J Gen Virol 2007, 88: 13-18. 10.1099/vir.0.82419-0PubMedView ArticleGoogle Scholar
- Shin YK, Li Y, Liu Q, Anderson DH, Babiuk LA, Zhou Y: SH3 binding motif 1 in influenza A virus NS1 protein is essential for PI3K/Akt signaling pathway activation. J Virol 2007, 81: 12730-12739. 10.1128/JVI.01427-07PubMedPubMed CentralView ArticleGoogle Scholar
- Y Li, Anderson DH, Liu Q, Zhou Y: Mechanism of influenza A virus NS1 protein interaction with the p85beta, but not the p85alpha, subunit of phosphatidylinositol 3-kinase (PI3K) and up-regulation of PI3K activity. J Biol Chem 2008, 283: 23397-23409. 10.1074/jbc.M802737200View ArticleGoogle Scholar
- Hale BG, Kerry PS, Jackson D, Precious BL, Gray A, Killip MJ, Randall RE, Russell RJ: Structural insights into phosphoinositide 3-kinase activation by the influenza A virus NS1 protein. PNAS 2010, 107: 1954-1959. 10.1073/pnas.0910715107PubMedPubMed CentralView ArticleGoogle Scholar
- Ehrhardt C, Marjuki H, Wolff T, Nurnberg B, Planz O, Pleschka S, Ludwig S: Bivalent role of the phosphatidylinositol-3-kinase (PI3K) during influenza virus infection and host cell defence. Cell Microbiol 2006, 8: 1336-1348. 10.1111/j.1462-5822.2006.00713.xPubMedView ArticleGoogle Scholar
- Shin YK, Liu Q, Tikoo SK, Babiuk LA, Zhou Y: Effect of the phosphatidylinositol 3-kinase/Akt pathway on influenza A virus propagation. J Gen Virol 2007, 88: 942-950. 10.1099/vir.0.82483-0PubMedView ArticleGoogle Scholar
- Ehrhardt C, Wolff T, Pleschka S, Planz O, Beermann W, Bode JG, Schmolke M, Ludwig S: Influenza A virus NS1 protein activates the PI3K/Akt pathway to mediate antiapoptotic signaling responses. J Virol 2007, 81: 3058-3067. 10.1128/JVI.02082-06PubMedPubMed CentralView ArticleGoogle Scholar
- Zhirnov OP, Klenk HD: Control of apoptosis in influenza virus-infected cells by up-regulation of Akt and p53 signaling. Apoptosis 2007, 12: 1419-1432. 10.1007/s10495-007-0071-yPubMedView ArticleGoogle Scholar
- Ehrhardt C, Ludwig S: A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathway. Cell Microbiol 2009, 11: 863-871. 10.1111/j.1462-5822.2009.01309.xPubMedView ArticleGoogle Scholar
- Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C: PI3K/Akt and apoptosis: size matters. Oncogene 2003, 22: 8983-8998. 10.1038/sj.onc.1207115PubMedView ArticleGoogle Scholar
- Hale BG, Randall RE, Ortin J, Jackson D: The multifunctional NS1 protein of influenza A viruses. J Gen Virol 2008, 89: 2359-2376. 10.1099/vir.0.2008/004606-0PubMedView ArticleGoogle Scholar
- Twu KY, Noah DL, Rao P, Kuo RL, Krug RM: The CPSF30 binding site on the NS1A protein of influenza A virus is a potential antiviral target. J Virol 2006, 80: 3957-3965. 10.1128/JVI.80.8.3957-3965.2006PubMedPubMed CentralView ArticleGoogle Scholar
- Li W, Wang G, Zhang H, Zhang D, Zeng J, Chen X, Xu Y, Li K: Differential suppressive effect of promyelocytic leukemia protein on the replication of different subtypes/strains of influenza A virus. Biochem Biophys Res Commun 2009, 389: 84-89. 10.1016/j.bbrc.2009.08.091PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.